2017
Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease
Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease. Journal Of The American Heart Association 2017, 6: e006044. PMID: 29021274, PMCID: PMC5721834, DOI: 10.1161/jaha.117.006044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAortic ValveAortic Valve StenosisComorbidityDatabases, FactualEchocardiographyFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidneyMaleMiddle AgedMitral ValveMitral Valve InsufficiencyNorth CarolinaPrevalencePrognosisProportional Hazards ModelsRenal Insufficiency, ChronicRetrospective StudiesRisk FactorsSeverity of Illness IndexSex FactorsTime FactorsConceptsChronic kidney diseaseFive-year survival estimatesNon-CKD patientsCKD patientsMitral regurgitationMR severityKidney diseaseSurvival estimatesCoronary artery bypassGlomerular filtration ratePercutaneous coronary interventionSevere mitral regurgitationValvular heart diseaseSerum creatinine valuesAdverse prognostic markerRegurgitant valve lesionsIndex echocardiogramSevere ASArtery bypassIntervention patientsValve lesionsValve surgeryCoronary interventionHazard ratioHeart failure
2013
Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart B, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial. JAMA 2013, 310: 2533-2543. PMID: 24247300, PMCID: PMC3934929, DOI: 10.1001/jama.2013.282190.Peer-Reviewed Original ResearchConceptsLow-dose dopamineAcute heart failureCumulative urine volumeRenal dysfunctionCystatin C levelsHeart failureRenal functionUrine volumeDiuretic therapyPlacebo-controlled clinical trialEnd pointPooled placebo groupCoprimary end pointsSecondary end pointsHours of admissionC levelsSerum cystatin CDose dopaminePlacebo groupActive treatmentClinical outcomesRandomized trialsClinical trialsCystatin CMAIN OUTCOME
2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney International 2011, 81: 568-576. PMID: 22189843, DOI: 10.1038/ki.2011.417.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBiomarkersBlack or African AmericanBlood PressureCalcium Channel BlockersCardiovascular DiseasesChi-Square DistributionCreatinineDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionIncidenceKaplan-Meier EstimateKidneyKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesUp-RegulationConceptsHigh cardiovascular riskNon-black patientsSerum creatinineCardiovascular riskEnd-stage renal diseaseBlood pressure goalsHypertensive black patientsAcute hemodynamic effectsEffective antihypertensive treatmentKidney disease progressionGlomerular filtration rateDouble-blinded mannerEvent-driven trialDisease end pointsACCOMPLISH trialAntihypertensive treatmentRenal outcomesEGFR lossHemodynamic effectsRenal diseaseBlack patientsBlack ethnicityFiltration rateDisease progressionPatients
2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity
2008
Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study
Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. European Heart Journal 2008, 30: 56-65. PMID: 19001474, DOI: 10.1093/eurheartj/ehn499.Peer-Reviewed Original ResearchConceptsHigh-risk myocardial infarctionMyocardial infarctionHeart failureIndependent predictorsLA sizeHF hospitalizationVentricular dysfunctionFirst monthBaseline independent predictorsVALIANT Echo studyLeft ventricular dysfunctionGlomerular filtration rateLeft atrial sizeBody surface areaBaseline LAVICause deathAtrial sizeLA enlargementAtrial remodellingEchocardiography studyLA remodellingLA volumeAdverse outcomesLV massFiltration rateComparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus
Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal Of Cardiology 2008, 101: 925-929. PMID: 18359309, DOI: 10.1016/j.amjcard.2007.11.037.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRenal dysfunctionRenal functionMyocardial infarctionCV outcomesDiabetes mellitusHigh-risk acute myocardial infarctionCox proportional modelingAdverse CV outcomesComposite cardiovascular eventsComposite end pointIndependent risk factorRenal Disease equationGlomerular filtration rateReduced renal functionBaseline creatinineCV eventsMean eGFRCardiovascular eventsCV diseaseCV riskVentricular dysfunctionCardiovascular riskHeart failureOverall mortality
2007
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction The VALIANT Echo Study
Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD. The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction The VALIANT Echo Study. Journal Of The American College Of Cardiology 2007, 50: 1238-1245. PMID: 17888840, DOI: 10.1016/j.jacc.2007.06.018.Peer-Reviewed Original ResearchConceptsLeft ventricular mass indexRenal impairmentHeart failureMyocardial infarctionRenal functionCardiac structureReduced eGFRSystolic functionLA volumeSmaller LVHigher left ventricular mass indexLarger left atrial volumeInfarct segment lengthMitral deceleration timeVALIANT Echo studyMultivariable Cox regressionAdverse cardiovascular outcomesLeft ventricular dysfunctionNormal renal functionOutcome of deathRight ventricular functionVentricular mass indexGlomerular filtration rateAdditional prognostic informationLarger LA volumes
2004
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal Of Medicine 2004, 351: 1285-1295. PMID: 15385655, DOI: 10.1056/nejmoa041365.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCardiovascular DiseasesChronic DiseaseCreatinineDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsRisk FactorsSurvival RateTetrazolesValineValsartanConceptsGlomerular filtration rateAcute myocardial infarctionMyocardial infarctionCardiovascular outcomesHeart failureRisk factorsAcute Myocardial Infarction trialFour-component ModificationNonfatal cardiovascular outcomesMyocardial Infarction trialUse of aspirinComposite cardiovascular eventsComposite end pointRenal Disease equationCongestive heart failureMild renal diseaseRisk of deathCoronary revascularization proceduresMajor risk factorSerum creatinine measurementsBody surface areaCardiovascular causesKillip classRenal eventsCardiovascular complications